Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network - Université de Rennes Accéder directement au contenu
Communication Dans Un Congrès Année : 2022

Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network

Domaines

Cancer

Dates et versions

hal-04071489 , version 1 (17-04-2023)

Identifiants

Citer

Murielle Roussel, Michelle Pirotte, Ornella Rizzo, Kentin Queru, Thomas Chalopin, et al.. Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network. 64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.10086-10087, ⟨10.1182/blood-2022-166224⟩. ⟨hal-04071489⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More